Moser Wealth Advisors LLC Sells 629 Shares of Merck & Co., Inc. $MRK

Moser Wealth Advisors LLC lowered its position in shares of Merck & Co., Inc. (NYSE:MRK) by 16.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,135 shares of the company’s stock after selling 629 shares during the quarter. Moser Wealth Advisors LLC’s holdings in Merck & Co., Inc. were worth $248,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Prentice Wealth Management LLC boosted its position in shares of Merck & Co., Inc. by 4.7% during the 2nd quarter. Prentice Wealth Management LLC now owns 9,410 shares of the company’s stock worth $745,000 after purchasing an additional 425 shares in the last quarter. Strata Wealth Advisors LLC bought a new position in shares of Merck & Co., Inc. during the 2nd quarter worth about $231,000. FSM Wealth Advisors LLC boosted its position in shares of Merck & Co., Inc. by 82.3% during the 2nd quarter. FSM Wealth Advisors LLC now owns 8,867 shares of the company’s stock worth $717,000 after purchasing an additional 4,003 shares in the last quarter. Principle Wealth Partners LLC boosted its position in shares of Merck & Co., Inc. by 3.6% during the 2nd quarter. Principle Wealth Partners LLC now owns 76,755 shares of the company’s stock worth $6,076,000 after purchasing an additional 2,697 shares in the last quarter. Finally, Granite Harbor Advisors Inc. boosted its position in shares of Merck & Co., Inc. by 25.4% during the 2nd quarter. Granite Harbor Advisors Inc. now owns 4,595 shares of the company’s stock worth $364,000 after purchasing an additional 932 shares in the last quarter. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Trading Down 0.4%

NYSE:MRK opened at $87.25 on Friday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.17 and a current ratio of 1.42. The firm has a market cap of $217.92 billion, a price-to-earnings ratio of 13.44, a price-to-earnings-growth ratio of 0.96 and a beta of 0.37. Merck & Co., Inc. has a 52 week low of $73.31 and a 52 week high of $106.62. The firm has a 50-day moving average price of $84.37 and a two-hundred day moving average price of $81.48.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, July 29th. The company reported $2.13 EPS for the quarter, beating the consensus estimate of $2.03 by $0.10. The firm had revenue of $15.81 billion during the quarter, compared to analyst estimates of $15.92 billion. Merck & Co., Inc. had a net margin of 25.79% and a return on equity of 41.05%. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. On average, equities analysts expect that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on MRK shares. Wells Fargo & Company cut their price objective on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 30th. Morgan Stanley lowered their target price on shares of Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating on the stock in a report on Thursday, July 10th. Berenberg Bank lowered shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and lowered their target price for the stock from $100.00 to $90.00 in a report on Wednesday, September 17th. Citigroup initiated coverage on shares of Merck & Co., Inc. in a report on Monday, October 13th. They issued a “neutral” rating and a $95.00 target price on the stock. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Merck & Co., Inc. in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $104.33.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.